Unknown

Dataset Information

0

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.

ABSTRACT: Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast cancer lending support to the development of drugs targeting the cell cycle control machinery, like the inhibitors of the cycline-dependent kinases (CDK) 4 and 6. Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. These agents have been effective in improving the clinical outcomes, but the development of intrinsic or acquired resistance can limit the efficacy of these treatments. Clinical and translational research is now focused on investigation of the mechanism of sensitivity/resistance to CDK4/6 inhibition and novel therapeutic strategies aimed to improve clinical outcomes. This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new biomarkers of response, and the biological rationale for new combination strategies of treatment.

SUBMITTER: Piezzo M 

PROVIDER: S-EPMC7554788 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast cancer lending support to the development of drugs targeting the cell cycle control machinery, like the inhibitors of the cycline-dependent kinases (CDK) 4 and 6. Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. These agents have been effective in improving the clinical outcomes, but the development of  ...[more]

Similar Datasets

Unknown Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
| S-EPMC6236629 | biostudies-literature
Unknown Therapeutic targeting of cancer cell cycle using proteasome inhibitors.
| S-EPMC3584802 | biostudies-other
Unknown Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer
| S-EPMC10891408 | biostudies-literature
Unknown eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.
| S-EPMC7132330 | biostudies-literature
Unknown Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.
| S-EPMC9932145 | biostudies-literature
Unknown CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal
| S-SCDT-EMBOJ-2021-108599 | biostudies-other
Unknown CDK4/6 inhibitors in advanced breast cancer, what is beyond?
| S-EPMC6683209 | biostudies-literature
Unknown Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
| S-EPMC7237121 | biostudies-literature
Unknown The role of CDK4/6 inhibitors in early breast cancer.
| S-EPMC8184648 | biostudies-literature
Unknown Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture.
| S-EPMC7653349 | biostudies-literature